Introduction
============

During the two last decades, a major step in the understanding of brain functions and dysfunctions has been to consider that not only neurons are at the center of these processes but that also their glial environment is actively involved. This statement is particularly true for astrocytes, a major glial cell population that establishes tight morphological and functional interactions with neurons ([@B27]; [@B73]) leading to the concept of the "tripartite synapse" (see [@B2]; [@B58]). In brain pathologies and mental illness this partnership is impaired, contributing to severe neuronal defects and even in certain cases leading to neuronal death ([@B23]; [@B4]; [@B57]). Such alterations in neuroglial interaction start to be investigated in order to identify and develop alternative therapeutic approaches that target astrocytes instead of solely neurons ([@B9]; [@B41]; [@B72]). Following this strategy, the objective is to act on a specific astroglial molecular constituent known to regulate neuronal activity and/or survival. Based on these requirements astroglial connexins (Cxs), a family of membrane proteins, may be considered as a good candidate. Indeed, Cxs are highly expressed in astrocytes compared to all other brain cell populations (see [@B61]), including neurons, and they have been reported to interplay with synaptic activity and plasticity ([@B56]), animal behavior ([@B66]), and neuronal survival ([@B20]; [@B19]). Besides, the expression and function of astroglial Cxs are affected in neurodegenerative diseases ([@B34]; [@B37]; [@B69]), ischemia and stroke ([@B52]), epilepsy ([@B47]), demyelinating diseases ([@B10]) and cancer ([@B49]). Much less is known about the status, i.e., expression and function, of Cxs in astrocytes in non-neurodegenerative mood disorders such as depression, while those pathologies are associated to a reduction in the number of astrocytes and a decrease in GFAP immunoreactivity (see [@B59]).

Connexins are the molecular constituents of gap junctions that are membrane specializations consisting of dense aggregates of large pore channels formed by two paired hexamers of Cxs. These gap junction channels extend from one cell into an adjacent cell and mediate a unique direct cytoplasm-to-cytoplasm communication. These channels are poorly selective for ions and for small molecular weight signaling molecules, thus they allow extensive ionic and biochemical exchanges between cells ([@B29]). In astrocytes, gap junction channels provide the basis for ionic homeostasis, particularly for potassium buffering and intercellular calcium signaling. They are also involved in biochemical and metabolic coupling (see [@B61]). Under certain conditions Cxs can also operate as half of a gap junction channel, named "hemichannel," representing another functional state that provides a pathway suitable for autocrine as well as paracrine interactions in the brain. In astrocytes, connexin hemichannels are permeable to ions and are involved in the release of gliotransmitters such as ATP and glutamate ([@B75]; [@B32]; [@B1]), the uptake of glucose ([@B62]) and the eﬄux of glutathione ([@B60]; [@B74]). In astrocytes two major Cxs have been identified, Cx43 and Cx30, which are not expressed in other brain cell types and are characterized by different developmental and regional patterns of expression ([@B48]). Both Cxs contribute to gap junctional communication but so far only hemichannels made by Cx43 have been reported to be functional in astrocytes (see [@B24]).

The information concerning astroglial Cxs and depression is based on two kinds of observations available from the literature. Firstly, those that report changes in the expression of astroglial Cxs from depressive patients, persons having committed suicide or from animal models of depression. Indeed, a Canadian study of postmortem generated microarray data suicide completers indicated that the expression level of Cx43 and Cx30 is reduced in dorsal lateral prefrontal cortex ([@B15]) and in the locus coeruleus ([@B5]). In addition, a recent study has reported that the expression of Cx43 is reduced in postmortem brains from patients suffering from major depressive disorder or comorbid depression relative to healthy subjects ([@B44]). Also, [@B67] have reported a decrease in diffusion of gap junction channel-permeable dye and expression of Cx43 in the prefrontal cortex in rats subjected to chronic unpredictable stress. Secondly, on the other side treatment with antidepressants also results in changes in the expression level of Cx43 in astrocytes as indicated in **Table [1](#T1){ref-type="table"}**. Five antidepressants, from three different therapeutic classes, have been tested in cellular and animal models; results indicate that 24--48 h treatment induces an increase in Cx43 expression at mRNA and/or protein levels. This is particularly the case for fluoxetine that has been tested in several models ([@B17]; [@B46]; [@B67]). However, there is little information about the effect of these drugs on the functional status of gap junctional communication and none about hemichannel activity. So far based on this literature it is tempting to deduce and summarize that depressive brains show a down-regulation of Cx43 while antidepressant treatments favor its up-regulation (see [@B59]). Nevertheless, an important clue concerning Cxs is to identify the functional consequences of these treatments on Cx43-based channels since changes in level of expression can have unpredictable consequences on their function. In order to address this question we have carried out a systematic test of seven antidepressants on gap junctional communication and hemichannel activity in primary cultures of astrocytes, known to express only Cx43 ([@B12]; [@B22]; [@B36]). The present study indicates that when used at a non-toxic and clinically relevant concentration they have differential effects on both channel functions leading to a more complicated global view of their action on intercellular communication mediated by Cx43 in astrocytes.

###### 

Summary table of the effects of antidepressants on Cx43 expression and gap junctional function in astrocytes.

  Antidepressant   Class   Effect on Cx43 expression   Effect on Cx43 function    Model                                      Treatment (dose and time)   Reference
  ---------------- ------- --------------------------- -------------------------- ------------------------------------------ --------------------------- -----------
  Amitriptyline    TCA     Increase (mRNA, protein)    Increase (gap junction)    Primary cultures rat cortical astrocytes   25 μM, 48 h                 [@B45]
                                                                                                                                                         
                                                                                                                                                         
  Clomipramine     TCA     Increase (protein)          NT                         Primary culture rat cortical astrocytes    10 μM, 48 h                 [@B45]
                                                                                                                                                         
                                                                                                                                                         
  Fluoxetine       SSRI    Increase (protein)          NT                         Rat *in vivo* Prefrontal cortex            20 mg/kg i.p. for 21 days   [@B17]
                                                                                                                                                         
                                                                                                                                                         
  Fluoxetine       SSRI    Increase (mRNA, protein)    NT                         Human astrocytoma cell line                10, 20 μg/ml 24 h           [@B46]
                                                                                                                                                         
                                                                                                                                                         
  Fluoxetine       SSRI    Increase (protein)          No effect (gap junction)   Rat *in vivo* Prefrontal cortex            10 mg/kg 21 days            [@B67]
                                                                                                                                                         
                                                                                                                                                         
  Duloxetine       SNRI    Increase (mRNA, protein)    No effect (gap junction)   Rat *in vivo* Prefrontal cortex            10 mg/kg 21 days            [@B67]
                                                                                                                                                         
                                                                                                                                                         
  Fluvoxamine      SSRI    Increase (protein)          NT                         Primary cultures rat cortical astrocytes   25 μM 48 h                  [@B45]

Materials and Methods {#s1}
=====================

All experiments were performed according to the European Community Council Directives of 2010/63/UE and all efforts were made to minimize the number of animals. This study was carried out in accordance with the recommendations of the Ethic Committee 59, Paris, France and received the approval of the Scientific Committee of the animal facilities of the Collège de France.

Cortical Astrocyte Cultures
---------------------------

Primary astrocyte cultures were prepared from the cortex of newborn (1--2 days) OF1 mice as previously described ([@B43]). For western blot and scrape-loading dye-transfer experiments, cells were seeded on polyornithine-coated 35-mm-diameter dishes (Nunc, Roskilde, Denmark) at a density of 5 × 10^5^cells/mL. For hemichannel experiments cells were seeded (2 × 10^5^ cells per well) on glass coverslips (Gassalem, Limeil-Brévannes, France) placed inside 24-round-well plate; area 1.9 cm2/well; (NunClon, Thermoscientific, Atlanta, GA, USA). Cellular medium, DMEM (Sigma--Aldrich, St-Louis MO, USA), supplemented with penicillin (5 U/ml), streptomycin (5 μg/ml; Invitrogen, Carlsbad, CA, USA), fungizone amphotericin B (500 ng/mL; Gibco, Life Technologies, Carlsbad, CA, USA), and 10% FCS (Hyclone, Logan, UT, USA), was changed twice a week. When cells reached confluence, around 10 days *in vitro* (DIV), they were harvested with trypsin-EDTA (Invitrogen). The medium was changed twice a week until the experiments were carried out. In order to characterize the proportion of microglia in primary culture of astrocytes, the two cell types were identified by immunostaining with Isolectine B4 and GFAP antibodies, respectively.

Products and Cell Treatments
----------------------------

Astrocyte cultures were treated for 24 h with lipopolysaccharide (LPS, 1 μg/ml) and/or the following antidepressants: fluoxetine, duloxetine, paroxetine, reboxetine, amitriptyline, imipramine, venlafaxine (5, 10, or 20 μM, Sigma--Aldrich, Saint-Louis, MO, USA). Carbenoxolone (50 μM, Sigma--Aldrich) was used as positive inhibitor control for gap junction channels. Drugs were prepared either in H~2~0 or DMSO. Control cells received no treatment and were previously studied with vehicle (H20 or DMSO) which induced no changes in comparison with untreated cells.

Determination of Gap Junctional Communication
---------------------------------------------

Experiments were performed by using the scrape-loading dye-transfer technique, as previously described ([@B43]). Briefly, cells were incubated at room temperature for 10 min in HEPES buffered salt solution containing (in mM): NaCl, 140; KCl, 5.4; CaCl~2~, 1.8; MgCl~2~, 1; glucose, 10; HEPES, 5 at pH 7.4. Cells were then washed with a calcium-free HEPES solution for 1 min and the scrape loading and dye transfer assay (see [@B25]) was carried out in the same calcium-free solution containing Lucifer yellow CH (427 Da, 1 mg/ml). One minute after scraping procedure, cells were washed with the HEPES solution and then Lucifer yellow loaded in the cells was allowed to diffuse through gap junction channels for 8 min. Photomicrographs were taken and data were quantified using NIS Nikon software. In all experiments, the fluorescence area of the first row of cells initially loaded, as measured in the presence of the gap junction channel inhibitor carbenoxolone (50 μM, 24 h), was subtracted from the total fluorescence area.

Ethidium Bromide Uptake Experiments in Cortical Astrocyte Cultures
------------------------------------------------------------------

Following 10 min exposure to 5 μM ethydium bromide (EtBr), cells were washed with HEPES buffered salt solution containing (in mM): NaCl, 140; KCl, 5.4; CaCl~2~, 1.8; MgCl~2~, 1; glucose, 10; HEPES, 5 at pH 7.4. After 10 min in fixing solution (4% paraformaldehyde in 0.12 M buffer phosphate) and rinsing with phosphate buffered saline (PBS), cells were mounted in Fluoromount-G mounting medium ([@B54]). Images of astrocyte cultures were taken with a 40× objective using a confocal laser-scanning microscope (Leica TBCS SP5). Stacks of consecutive confocal images for 10 μm at 0.49 μm intervals were acquired with an argon ion laser at 488 nm. Confocal images of EthBr uptake were analyzed with Image J software. The EtBr fluorescence intensity in the nuclei of astrocytes in each image was measured and the average of six images of different areas in the same culture was calculated the final measurement of dye uptake in that culture.

Western Blot
------------

After 24 h of treatment, cultures were rinsed with PBS 1X and added 75 μL of a solution containing protease and phosphatase inhibitors (orthovanadate 1 mM; α-glycerophosphate 10 mM), and complete miniprotease inhibitor (Roche Diagnostics, Meylan, France). Cells were then harvested by scraping with a rubber policeman and pelleted cells were added 20 μL of 5X Laemmli sample buffer. Samples were boiled for 5 min, placed on ice, and lysed by sonication (Ultrasonic cell disrupter, Microson, Bruxelles, Belgium). Then, samples were stored at -20°C. Proteins were measured with the Bio-Rad protein assay (Bio-Rad laboratories, Richmond, CA, USA). For each cell lysate sample, 20 μg of proteins were separated on Bis-Tris 4--12% NuPAGE gels and electro-transferred to nitrocellulose sheets as previously described ([@B54]). Non-specific protein binding was blocked by incubation of nitrocellulose sheets in tris-buffered saline (TBS) -- Tween -- milk solution (500 mL TBS 1X; 500 μL Tween 20X; non-fat powder milk 25 g) for 1 h. Blots were then incubated overnight with primary antibody mouse Cx43 1:500 (Transduction Laboratories, Le Pont de Claix, France) at 4°C, followed by 4 × 15 min PBS washes. Blots were incubated with goat anti-mouse antibody 1:2500 conjugated to horseradish peroxidase (Tébu, Le Perray-En-Yveline, France). Immunoreactivity was detected by ECL detection using the SuperSignal kit (Pierce, Rockford, IL, USA) according to instructions. Blots were then reprobed with mouse monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase peroxidase (Sigma--Aldrich, 1:10,000) to check the protein load. Chemiluminescence imaging was performed on a LAS4000 (Fujifilm, Stamford, CT, USA). Semiquantitative densitometric analysis was performed with ImageJ software after scanning the bands.

Statistical Analysis
--------------------

For each data group, results are expressed as mean ± SEM and *n* refers to the number of independent experiments. Kruskal--Wallis test and one-way ANOVA, followed, respectively, by Dunn and Bonferroni post tests, were used as well as unpaired *t*-test. Differences are considered significant at ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 versus control, +*P* \< 0.05, ++*P* \< 0.01, and +++*P* \< 0.001 vs. LPS. GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA) was used for calculations.

Results
=======

The doses of the antidepressants were chosen in accordance with literature addressing the neuropharmacokinetics of the tested molecules of interest. Accordingly, cultured cortical astrocytes were treated with concentrations identical to those reported for brains of human or rodent after treatment with clinically relevant doses from *in vivo* studies: for fluoxetine, 20 μM in human brain is achieved at 20 mg/day (see [@B30]); for venlafaxine, 10 μM in mice brain is reached at 20 mg/kg ([@B33]); for duloxetine, 4.2 mg/kg in rat leads to 10 μM in brain ([@B35]). For the other molecules (amitriptyline, imipramine, paroxetine, reboxetine) the doses were selected below cell toxicity that was identified by microscopic examination of astrocyte cultures treated for 24 h, related to changed cell morphology and entry of Lucifer yellow into damaged cells. More precisely the lack of toxicity of the selected doses was routinely validated by the absence of Lucifer yellow unspecific uptake in area far from the scrape lines in scrape-loading dye-transfer experiments (see **Figure [1A](#F1){ref-type="fig"}**). Based on these criterions all molecules were tested at concentrations between 5 and 20 μM (24 h) for toxicity; we observed that fluoxetine at 20 μM, paroxetine 10 μM, and duloxetine 20 μM were toxic at these indicated doses, consequently these molecules were tested at lower doses.

![**Modulation of astrocyte Cx43 gap junctional communication after 24-h treatment by seven antidepressants in mice cortical astrocyte cultures**. Amitriptyline (AMIT), imipramine (IMI), fluoxetine (FLUOX), paroxetine (PAROX), reboxetine (REBOX), duloxetine (DULOX), and venlafaxine (VENLA) were added from 5 to 20 μM in cellular medium during 24 h, gap junctional communication was evaluated by the scrape loading dye transfer method. **(A)** Pictures of control, paroxetine 5 μM, venlafaxine 5 μM, and amitriptyline 20 μM, illustrate the Lucifer yellow spreading through astrocyte gap junctions for these different treatments. **(B)** Summary diagram of junctional communication in vehicle-treated cells (control group) and after antidepressant treatment. Note that the values are normalized to carbenoxolone (50 μM, 24 h). Data are the means ± SEM *n* = 3--7 per group, ^∗∗∗^*p* \< 0.001, ^∗∗∗∗^*p* \< 0.0001 vs. control, Kruskal--Wallis test and one-way ANOVA followed, respectively, by Dunn and Bonferroni post test. Scale bar 20 μM.](fncel-09-00495-g001){#F1}

The first question addressed during this screening with antidepressants was their effect on the level of Cx43 expression investigated by western blotting. As indicated in **Table [2](#T2){ref-type="table"}**, the seven tested antidepressants did not significantly modify the level of expression of Cx43 studied in cultured cortical mouse astrocytes (*n* = 3--6 per group, *p* \> 0.05 One way ANOVA, Dunn post test).

###### 

Summary table of the effect of seven antidepressants for four different classes: tricyclic (TCA), selective serotonin reuptake inhibitor (SSRI), noradrenaline reuptake inhibitor (NRI), serotonin noradrenaline reuptake inhibitor (SNRI), on Cx43 expression and channel functions in cultured astrocytes.

  Antidepressant   Class   Concentration tested (μM)   Cx43 expression         Effect on gap junctional coupling   Effect on hemichannels   
  ---------------- ------- --------------------------- ----------------------- ----------------------------------- ------------------------ --
  Amitriptyline    TCA     20                          No significant effect   Inhibition                          Mild inhibition          
  Imipramine       TCA     20                          No significant effect   No effect                           Mild inhibition          
  Fluoxetine       SSRI    10                          No significant effect   Inhibition                          Total inhibition         
  Paroxetine       SSRI    5                           No significant effect   Increase                            Total inhibition         
  Reboxetine       NRI     10                          No significant effect   No effect                           Mild inhibition          
  Duloxetine       SNRI    5                           No significant effect   No effect                           Total inhibition         
  Venlafaxine      SNRI    5                           No significant effect   Inhibition                          Mild inhibition          

The effect of the selected antidepressants on gap junctional communication was then tested by using the scrape-loading dye transfer technique (see [@B25]). In control condition after 10 min the Lucifer yellow diffuses widely perpendicular to the scrape line that indicates a high level of gap junctional communication (**Figure [1A](#F1){ref-type="fig"}**, control). As illustrated in **Figure [1B](#F1){ref-type="fig"}**, three different effects were observed. Three antidepressants, amitriptyline (20 μM; **Figure [1A](#F1){ref-type="fig"}**), fluoxetine (10 μM), and venlafaxine (5 μM; **Figure [1A](#F1){ref-type="fig"}**) reduced intercellular dye spread by 57% (*n* = 6), 25% (*n* = 6), and 15% (*n* = 6), respectively. In contrast, paroxetine (5 μM; **Figure [1A](#F1){ref-type="fig"}**) increased dye coupling by 19% (*n* = 7). Finally, imipramine (20 μM, *n* = 3), reboxetine (10 μM, *n* = 6) and duloxetine (5 μM, *n* = 9) had no statistically significant action on the level of intercellular communication between astrocytes, neither at these doses nor at higher non-toxic doses.

In normal condition, astrocytes in culture as well as in acute slices are characterized by a high level of gap junctional communication and low hemichannel activity ([@B3]; [@B62]; but see [@B7]). However, in most pathological situations involving brain inflammation, a reactive gliosis is associated with elevated hemichannel activity in astrocytes (see [@B4]; [@B24]). Such low hemichannel activity was also observed in our culture condition (**Figure [2A](#F2){ref-type="fig"}**). Therefore, to induce hemichannel activity we treated our cortical primary cultures, in which 11% (*n* = 9) of isolectin B4-positive microglia versus GFAP-positive astrocytes were present, with the endotoxin LPS. As already reported for *in vitro* astrocytes ([@B62]), we observed that LPS treatment (1 μg/ml, 24 h) inhibited gap junctional communication by 64% (*n* = 6), in such condition we found that the antidepressants amitriptyline (20 μM, *n* = 4), imipramine (20 μM, *n* = 4), venlafaxine (5 μM, *n* = 3), and duloxetine (5 μM, *n* = 4) did not reverse the inhibition induced by LPS, when co-treated during 24 h in astrocyte cultures. However, paroxetine (5 μM, *n* = 4) and reboxetine (10 μM, *n* = 3) reversed LPS-induced uncoupling, in a low but significant manner, respectively, by 17% (*n* = 4) and 10% (*n* = 3) whereas fluoxetine (10 μM) improved it by 10% (*n* = 4; data not illustrated). Moreover, we found that LPS treatment (1 μg/ml, 24 h) increased by 104% (*n* = 7) the uptake of ethidium bromide (EtBr) in GFAP-positive astrocytes indicating that, as previously reported ([@B62]; [@B1]) hemichannels in cortical astrocytes were activated (**Figure [2A](#F2){ref-type="fig"}**). As expected EtBr uptake was inhibited by 93% (*n* = 3) in the presence of carbenoxolone (50 μM; 24 h) indicating that this uptake is mediated through hemichannel activity (**Figure [2B](#F2){ref-type="fig"}**). All the seven antidepressants tested had a significant inhibitor effect on the LPS-induced EtBr uptake, however, with difference in their efficiency. Indeed, fluoxetine (10 μM), paroxetine (5 μM), and duloxetine (5 μM; **Figure [2A](#F2){ref-type="fig"}**) had pronounced effect and inhibited EtBr uptake by 97% (*n* = 3), 93% (*n* = 3), and 111% (*n* = 4), respectively (**Figure [2B](#F2){ref-type="fig"}**). Meanwhile, amitriptyline (20 μM; **Figure [2A](#F2){ref-type="fig"}**), imipramine (20 μM), reboxetine (10 μM), and venlafaxine (5 μM) had milder effect with 45% (*n* = 6), 28% (*n* = 3), 52% (*n* = 3), and 23% (*n* = 4), respectively (**Figure [2B](#F2){ref-type="fig"}**).

![**Regulation of hemichannel activity after 24-h antidepressant treatments in mice cortical astrocytic cultures**. LPS 1 μg/mL was added 24-h before experiment to induce hemichannel opening and hemichannel activity was evaluated by using the ethidium bromide uptake assay. **(A)** Pictures of control, LPS alone, LPS + amitriptyline 20 μM, and LPS + duloxetine 5 μM uptake experiments. **(B)** Summary diagram of hemichannel activity in untreated astrocytes (CTRL) and after treatments with amitriptyline (AMIT), imipramine (IMI), fluoxetine (FLUOX), paroxetine (PAROX), reboxetine (REBO), duloxetine (DULOX), and venlafaxine (VENLA) were also added from 5 to 20 μM in cellular medium during 24 h. Carbenoxolone (CBX, 50 μM, 24 h) was used as a positive control for the inhibition of Cx43 hemichannels. Data are the means ± SEM *n* = 3--6 per group, ^∗∗∗^*p* \< 0.001 vs. control, +++*p* \< 0.001 vs. LPS, One-way ANOVA followed by Dunn post test. Scale bar 20 μM.](fncel-09-00495-g002){#F2}

Discussion
==========

The objective of the present study was to investigate the effects of a panel of antidepressants on the property of the astroglial Cx43, a membrane protein widely expressed in glial cells that contributes actively to neuroglial interaction in normal and disease brain (see [@B61]). For this purpose we undertook an *in vitro* screening of seven antidepressants from four different classes (TCA, SSRI, NRI, SNRI), all implied in serotonin and/or noradrenaline reuptake inhibition, to characterize their action on astroglial Cx43 at diverse levels: protein expression, gap junctional communication and hemichannel function. We selected a simple cellular system, primary cultures of mouse cortical and striatal astrocytes in which only Cx43 is detected ([@B12]; [@B22]; [@B36]). The tested concentrations were determined either based on the literature, when clinically relevant doses were available, or by establishing experimentally their threshold of toxicity for 24 h treatment (see Results section). While we did not observe any significant change in Cx43 protein level, we found that antidepressants had differential effects on astroglial Cx43-based gap junctional communication as summarized in **Table [2](#T2){ref-type="table"}**. These results are different compared those reported in the few articles that so far have addressed these properties for some of the antidepressants used in the present study, i.e., amitriptyline, fluoxetine, and duloxetine (see **Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**). Indeed, [@B67] and [@B45] reported, respectively, an enhancement in Cx43 mRNA and protein levels in astrocytes from cultured rat astrocytes treated with amitriptyline and in the prefrontal cortex of rats chronically treated with duloxetine ([@B67]; [@B45]). Additionally, two studies have also shown a rise in Cx43 protein levels in the prefrontal cortex after *in vivo* treatment with fluoxetine ([@B17]; [@B67]), as well as in human astrocytoma cultures ([@B46]). However, no changes in Cx43 gap junctional communication have been found after *in vivo* treatments with both fluoxetine and duloxetine in rats ([@B67]) whereas this Cx43 function was increased after amitriptyline treatment in cultured rat astrocytes ([@B45]). In our experiments (see **Table [2](#T2){ref-type="table"}**) only paroxetine (5 mM) was found to increase gap junctional communication while duloxetine (5 μM) has a slight, but not statistically significant increasing effect. Imipramine (20 μM) and reboxetine (10 μM) had no effect and an inhibition was observed with amitriptyline (20 μM), fluoxetine (10 μM), and venlafaxine (5 μM). These effects were not specific to a defined class of antidepressants and allow for taking a step back regarding results from other models. Indeed, our study demonstrates that the link between antidepressants and Cx43-mediated intercellular communication in astrocyte is likely more complex than the literature consensual interpretation concerning an increase of Cx43 expression and function, and that opposed effects are observed within a same therapeutic class. However, when pointing out the differences between our results and the current literature, several parameters must be taken into account. First, the models of study differed: we used cultured mouse astrocytes, while [@B67] and [@B17] worked *in vivo* on rats, and others used cell culture models from various species and cellular types in culture (human astrocytoma and rat astrocytes). Second, dosage, time, and chronicity of the treatments also differ. Indeed, our *in vitro* tested concentrations were non-toxic and similar to what is found in the brain in pharmacokinetics studies addressing clinically relevant doses for these molecules, and ranged from 1 to 100 μM in the literature. In literature, *in vitro* treatments were administered for several minutes to 48 h (see **Table [1](#T1){ref-type="table"}**). We treated for 24 h, as for example preliminary trials of 48-h treatments with amitriptyline (20 μM) induced cell toxicity. In addition, in the studies that were performed using *in vivo* models, animals received chronic treatment (see **Table [1](#T1){ref-type="table"}**) that certainly involved more integrated and complex mechanisms. Taken as a whole these information complete and extend the knowledge about the effect of antidepressants on gap junctional communication in astrocytes. Finally, as no changes in Cx43 expression were detected after treatment with antidepressant, we suggested that they act at the post-translational level.

Up-to-now there was no indication about the effect of antidepressants on the other channel function of Cx43 in astrocytes, i.e., the hemichannel activity. This lack of information can be attributed to the fact that for astrocytes this activity has been established much latter than the gap junction channel function and that hemichannels are weakly opened in normal conditions hence requiring a pathological context to be activated (see [@B3]; [@B24]). We confirmed this feature on untreated primary cortical cultures as the Cx channel inhibitor carbenoxolone had no significant no effect (data not shown) on the uptake of EtBr (see [@B25]). However, we took advantage that our LPS-stimulated cultures contained a non-negligible proportion of microglial cells (11%), a situation already identified to activated Cx43 hemichannels and to reduce gap junctional communication in astrocytes ([@B62]). Indeed, we previously showed that when LPS-stimulated microglia are co-cultured with astrocytes two pro-inflammatory cytokines are released, i.e., TNF-α and IL-1β, activating Cx43 hemichannel activity in astrocytes ([@B62]; [@B1]). Interestingly, LPS has been reported to cause time-dependent behavioral alterations with sickness behavior ([@B31]) and a depressive-like behavior observed 24 h after LPS challenge ([@B55]; [@B11]); and it is noteworthy that this effect is reversed by fluoxetine ([@B76]), imipramine ([@B70]), paroxetine and duloxetine ([@B51]). Besides, the level of TNF-α and IL-1β, are increased after LPS treatments in animal model, similarly to the increase observed in subjects with major depression disease ([@B64]; [@B65]; [@B13]; [@B28]). On this basis LPS has been proposed as an inducer of depressive-like context ([@B42]; [@B51]) confirming the interest of LPS in the evaluation of antidepressant mechanisms. Using the EtBr uptake assay we found that all tested antidepressants had an inhibitory effect on LPS-induced astroglial hemichannel activity. The effect on Cx43-based hemichannel function was correlated when considering the class of the antidepressants, the SSRIs (fluoxetine, paroxetine) induced a strong inhibition while the TCAs (amitriptyline, imipramine) and NRI (reboxetine) had mild effect, the treatment with SNRI (duloxetine, venlafaxine) resulting in mixed inhibition efficiency. Interestingly, several of these antidepressants are known to have an inhibitory effect on the production of pro-inflammatory cytokines, in particular TNF-α and IL-1β, fluoxetine ([@B8]; [@B68]; [@B71]), amitriptyline ([@B50]; [@B68]), paroxetine ([@B40]), and imipramine ([@B38]). Meanwhile venlafaxine, which presents the lowest inhibitory effect on LPS-induced hemichannel activity (23%), is the only tested compound that increased the level of TNF-α ([@B71]). Taken as a whole these results could support the idea that antidepressants may control Cx43 hemichannel activity through the production of TNF-a and/or IL-1β as the result of a reduction of microglial activation. However, just paroxetine and reboxetine modestly reversed the inhibition of gap junctional communication induced by LPS, it could consequently imply that antidepressant effects are not targeting microglia-released interleukins. It could also suggest that the antidepressant inhibitory effects on hemichannels are acting downstream to the microglial step and/or more directly on the Cx43 hemichannel function. Nevertheless, more work is needed to decipher the specific mechanisms involved in the regulation of astroglial Cx channels by antidepressants, an aim that is beyond the scope of the present study.

Interestingly, hemichannel activity in astrocytes has been shown to provide a pathway for glutamate release ([@B75]; [@B1]). Consequently, the antidepressant inhibitory action on hemichannel activity could support the current hypothesis of the action of these drugs on glutamine/glutamate metabolic cycle ([@B21]) and glutamate transmission ([@B26]; [@B63]) in the pathophysiology of major depression ([@B16]). Finally, glutamate gliotransmission mediated by Cx43 hemichannels has been recently reported to occur in a model of chronic restraint stress ([@B53]) which is admitted as a model inducing depressive-like symptoms in rodents ([@B39]).

The present study reflects the need to re-evaluate the statement according to which an alternative strategy for antidepressive treatments is to target astroglial Cx43 and to increase gap junctional communication. This proposition was solely based on reports indicating that several antidepressants favor Cx43 expression levels while a few have investigated their effect on the functional aspect, i.e., gap junctional communication. Based on the present results the effect of antidepressant drugs on astroglial gap junctions appears more complex than initially thought and suggests that Cx43 hemichannel activity in astrocytes may be part of the mode of action of these drugs. Finally, our observation, and in particular those related to hemichannel activity, could benefit to the understanding of the mode of action of antidepressants in other pathologies treated by antidepressants such as neuropathic pain ([@B14]; [@B18]) and for which the involvement of glial Cx43 hemichannel activity has been proposed ([@B6]).
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